SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Alembic Pharmaceuticals informs about company updates

21 Mar 2018 Evaluate

Alembic Pharmaceuticals has informed that the United States Food and Drug Administration (US FDA) has conducted an inspection at Alembic Pharmaceuticals Formulation Facility located at Panelav from 12th March, 2018 to 20th March, 2018. This was a scheduled inspection and at the end of the inspection, the US FDA issued a Form 483 with 3 observations. None of the observations are related to data integrity or repetitive in nature. The Company is preparing the response to the observations, which will be submitted to the US FDA shortly.

The above information is a part of company’s filings submitted to BSE.

 

Alembic Pharma Share Price

767.85 4.30 (0.56%)
22-Apr-2026 09:55 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1662.90
Dr. Reddys Lab 1214.90
Cipla 1225.70
Zydus Lifesciences 927.50
Lupin 2298.05
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×